Liquid biopsy for cancer is non-invasive and easily repeated, permitting molecular profiling and many other purposes with strong accuracy.

Blood-based biomarkers (BBMs) hold promise for a fast, convenient, and simple means to accurately diagnose Alzheimer's Disease.

We compared awareness in oncologists of selected biomarkers to the prevalence of actionable oncogenic mutations across cancers.

We examined RAS/KRAS trending and awareness for oncologists; results track strongly with the history of scientific KRAS advancements.

We analyzed trending and awareness patterns of NTRK and NTRK-targeting compounds in academic and community oncologists.

Awareness of new and emerging cancer biomarkers and compounds is vital so HCPs will test for and treat molecular oncogenic drivers.